
    
      To evaluate the therapeutic equivalence and safety of generic diclofenac epolamine 1.3% patch
      (Watson Laboratories, Inc.) and FlectorÂ® (diclofenac epolamine 1.3% patch) (Pfizer) in the
      treatment of acute pain due to minor ankle sprain.

      To demonstrate the superiority of the efficacy of the test and reference products over that
      of the vehicle control in the treatment of acute pain due to minor ankle sprain.

      To access application site reactions and patch adhesion between treatment groups.
    
  